Literature DB >> 18333156

Epidemiology and carcinogenesis of hepatocellular carcinoma.

Trishe Y-M Leong1, Anthony S-Y Leong.   

Abstract

The incidence of hepatocellular carcinoma (HCC) shows marked variation worldwide but the magnitude of this tumor is reflected by the occurrence of at least 1 million new cases annually and the uniformly dismal outlook with median survivals of <25 months after resection and <6 months with symptomatic treatment. The strikingly uneven distribution of this tumor parallels the prevalence of hepatitis B infection with rising incidence in western countries attributed to hepatitis C infection. Chronic hepatitis and cirrhosis constitute the major preneoplastic conditions in the majority of HCCs and may be related to other etiologic agents such as environmental chemical carcinogens including nitrites, hydrocarbons, solvents, organochlorine pesticides, and the chemicals in processed foods, cleaning agents, cosmetics and pharmaceuticals, as well as plant toxins such as anatoxins produced by fungi that cause spoilage of grain and food in the tropics. Genetic diseases such as genetic hematochromatosis, Wilson's disease, alpha-1-antitrypsin deficiency, and the inborn errors of metabolism including hereditary tyrosinemia and hepatic porphyria, are known to be associated with HCC. Numerous genetic alterations and the modulation of DNA methylation are recognized in HCC and it is likely that these genetic and epigenetic changes combine with factors involved in chronic hepatocyte destruction and regeneration to result in neoplastic growth and multiple molecular pathways may be involved in the production of subsets of hepatocellular tumors.

Entities:  

Year:  2005        PMID: 18333156      PMCID: PMC2023917          DOI: 10.1080/13651820410024021

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  78 in total

1.  Treatment of primary liver cancer in Singapore. A review of 3200 cases seen between January 1, 1977, and July 31, 1987.

Authors:  C J Oon; A Rauff; L K Tan
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  Diet and cancer--an overview.

Authors:  W C Willett; B MacMahon
Journal:  N Engl J Med       Date:  1984-03-08       Impact factor: 91.245

3.  The occurrence of hepatoma in the chronic form of hereditary tyrosinemia.

Authors:  A G Weinberg; C E Mize; H G Worthen
Journal:  J Pediatr       Date:  1976-03       Impact factor: 4.406

4.  Childhood primary hepatocellular carcinoma and hepatitis B virus infection.

Authors:  P L Cheah; L M Looi; H P Lin; S F Yap
Journal:  Cancer       Date:  1990-01-01       Impact factor: 6.860

5.  Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis.

Authors:  C Niederau; R Fischer; A Sonnenberg; W Stremmel; H J Trampisch; G Strohmeyer
Journal:  N Engl J Med       Date:  1985-11-14       Impact factor: 91.245

6.  Incidence and epidemiological factors of hepatocellular carcinoma in Valencia during the year 2000.

Authors:  M L García-Torres; A Zaragozá; R Giner; J Primo; J A del Olmo
Journal:  Rev Esp Enferm Dig       Date:  2003-06       Impact factor: 2.086

Review 7.  The epidemiology and natural history of HIV/HBV and HIV/HCV co-infections.

Authors:  Gail Mathews; Sanjay Bhagani
Journal:  J HIV Ther       Date:  2003-11

Review 8.  Hepatocellular carcinoma and African iron overload.

Authors:  I T Gangaidzo; V R Gordeuk
Journal:  Gut       Date:  1995-11       Impact factor: 23.059

Review 9.  Geographic variations in Wilson's disease.

Authors:  N S Chu; T P Hung
Journal:  J Neurol Sci       Date:  1993-07       Impact factor: 3.181

10.  Ataxia telangiectasia with hepatocellular carcinoma in a 15-year-old girl and studies of her kindred.

Authors:  S Weinstein; A G Scottolini; S Y Loo; P C Caldwell; N V Bhagavan
Journal:  Arch Pathol Lab Med       Date:  1985-11       Impact factor: 5.534

View more
  26 in total

1.  Role of operative therapy in non-cirrhotic patients with metastatic hepatocellular carcinoma.

Authors:  Victor Zaydfudim; Rory L Smoot; Clancy J Clark; Michael L Kendrick; Florencia G Que; Michael B Farnell; David M Nagorney
Journal:  J Gastrointest Surg       Date:  2012-05-30       Impact factor: 3.452

2.  Musashi-2 promotes hepatitis Bvirus related hepatocellular carcinoma progression via the Wnt/β-catenin pathway.

Authors:  Ming-Hai Wang; Shi-Yong Qin; Shu-Guang Zhang; Guang-Xin Li; Zhen-Hai Yu; Kun Wang; Bin Wang; Mu-Jian Teng; Zhi-Hai Peng
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

3.  Abrus agglutinin suppresses human hepatocellular carcinoma in vitro and in vivo by inducing caspase-mediated cell death.

Authors:  Subhadip Mukhopadhyay; Prashanta Kumar Panda; Durgesh Nandini Das; Niharika Sinha; Birendra Behera; Tapas Kumar Maiti; Sujit Kumar Bhutia
Journal:  Acta Pharmacol Sin       Date:  2014-05-05       Impact factor: 6.150

4.  Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis.

Authors:  Hiroshi Sogawa; Brian Shrager; Ghalib Jibara; Parissa Tabrizian; Sasan Roayaie; Myron Schwartz
Journal:  HPB (Oxford)       Date:  2012-08-30       Impact factor: 3.647

Review 5.  Situs Inversus Totalis (SIT) with Hepatocellular Carcinoma (HCC): A Rare Case Report and Review of 12 Other Cases.

Authors:  Rajan B Patel; Natvar R Gupta; Nitin C Vasava; Janak R Khambholja; Sanjay Chauhan; Amit Desai
Journal:  Indian J Surg       Date:  2012-10-10       Impact factor: 0.656

6.  Association between hepatitis C and hepatocellular carcinoma.

Authors:  Luis Jesuino de Oliveria Andrade; Argemiro D'Oliveira; Rosangela Carvalho Melo; Emmanuel Conrado De Souza; Carolina Alves Costa Silva; Raymundo Paraná
Journal:  J Glob Infect Dis       Date:  2009-01

7.  Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues.

Authors:  Ben-Dong Chen; Wen-Chao Zhao; Jian-Da Dong; Hui Sima
Journal:  Mol Biol Rep       Date:  2014-02-28       Impact factor: 2.316

8.  Hypermethylation reduces the expression of PNPLA7 in hepatocellular carcinoma.

Authors:  Xiaojiao Zhang; Jun Zhang; Rui Wang; Shicheng Guo; Huilu Zhang; Yanyun Ma; Qingmei Liu; Haiyan Chu; Xianghong Xu; Yitong Zhang; Dongqin Yang; Jiucun Wang; Jie Liu
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

9.  High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria.

Authors:  Eliane Sardh; Staffan Wahlin; Mikael Björnstedt; Pauline Harper; Dan E H Andersson
Journal:  J Inherit Metab Dis       Date:  2013-01-23       Impact factor: 4.982

10.  Silymarin downregulates COX-2 expression and attenuates hyperlipidemia during NDEA-induced rat hepatocellular carcinoma.

Authors:  Gopalakrishnan Ramakrishnan; Carmen Martha Elinos-Báez; Sundaram Jagan; Titto Alby Augustine; Sattu Kamaraj; Pandi Anandakumar; Thiruvengadam Devaki
Journal:  Mol Cell Biochem       Date:  2008-03-31       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.